$350 Million

Areteia Therapeutics, Inc.

Private Placement

Exclusive Placement Agent, July 2022

Series A Private Placement

Areteia Therapeutics is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners’ development unit, Validae Health.